Edgewise reports loss as it continues trials – BizWest bizwest.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizwest.com Daily Mail and Mail on Sunday newspapers.
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up to $17 37 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
– Overenrolled CANYON and advanced the global pivotal cohort, GRAND CANYON, of EDG-5506 in Becker muscular dystrophy –
– Advanced Phase 2 LYNX trial of EDG-5506 including new cohort for boys.
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 3 6% theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 3 6% themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.